Dr Lal Pathlabs

Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion

The company's revenue from operations also rose to Rs 603 crore in Q4FY25, a 10.5 per cent Y-o-Y growth from Rs 545 crore reported in Q4FY24

Dr Lal Path Labs Q4FY25 results: Net profit rises 83.2% to ₹155 crore

The company's consolidated net profit jumped 83.2 per cent year-on-year to Rs 1.55 billion (about $18 million) in the quarter ended March 31

Dr Lal Q3FY25 results: PAT jumps 19% to Rs 98 crore as volumes grow

As for Suburban Diagnostics, an arm of Dr Lal Pathlabs, revenue growth was 9.2 per cent in Q3

Dr Lal Path Labs Q3FY25 results: Net profit jumps 19% to Rs 96.7 crore

The company's consolidated net profit rose to Rs 96.7 crore ($11.2 million) in the three months to Dec. 31, from Rs 81.3 crore a year earlier, but fell short of analysts' estimate of Rs 97.69 crore

HMPV scare: Vijaya, Dr Lal Path, healthcare stocks in focus; Time to buy?

Apollo Hospitals, Vijaya Diagnostic and Narayana Hrudayalaya have given a fresh breakout on the daily scale. Charts show that these 5 healthcare related shares can rally up to 11 per cent.

F&O Market: Union Bank, Dabur see short build-up as Nifty tumbles 300pts

Union Bank stock futures plunged nearly 8% on the back of 54% increase in OI. On the other hand, Dr. Lal Path Labs and Metropolis Health witnessed long build-up on Monday; shows derivatives data.

Diagnostic demand rises in towns; organised players lead expansion plans

The Healthcare Federation of India reports that over 50 per cent of aspirational districts identified by NITI Aayog, which lack essential infrastructure, are served by diagnostic chains

Dr Lal PathLabs up 4% on strong September qtr results; more details here

The uptick in Dr Lal PathLabs's share price came on the back of a healthy September quarter of financial year 2025 (Q2FY25) earnings

Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%

The company, which operates 280 labs across India and is on track to open 15-20 new labs this year as part of its expansion efforts, is also exploring acquisitions in southern India

Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr

The company's consolidated net profit increased 18 per cent year-over-year to Rs 129 crore ($15.4 million), increasing for the sixth quarter in a row

Dr Lal PathLabs Q1 results: Net profit up by 29.1%, revenue rises by 11.3%

The company's revenue from operations rose to Rs 602 crore in Q1FY25, an 11.3 per cent Y-o-Y growth from Rs 541 crore reported in Q1FY24

Dr Lal PathLabs Q1FY25 results: Net profit rises 28% to Rs 106 cr

Consolidated net profit rose 28 per cent to Rs 106 cr (around $13 million) for the quarter ended June 30, beating analysts' estimate of Rs 99.27 cr, per LSEG

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill

Manchanda highlights that the 'white-spaces' for them are going deeper in strong markets

Dr Lal PathLabs Q4 results: Net profit jumps 49% to Rs 84.5 crore

Eyes expansion into Tier 3 and Tier 4 towns

Dr. Lal PathLabs Q4 results: Net profit rises 49% on healthy testing demand

The company's consolidated net profit jumped 49% year-on-year to Rs 84.5 crore ($10.1 million) in the fourth quarter

Preventive and wellness tests drive growth for diagnostic companies

Covid-19 led to increase in self-testing awareness, particularly about preventive and wellness services

Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%

Dr Lal PathLabs reported an increase in its network of Patient Service Centres (PSCs) and Pick-Up Centres (PUPs) across the country. It also reported a 2 per cent rise in revenue from Tier 3 cities

Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%

Dr Lal PathLabs reported an increase in its network of Patient Service Centres (PSCs) and Pick-Up Centres (PUPs) across the country. It also reported a 2 per cent rise in revenue from Tier 3 cities

Dr. Lal PathLabs Q3 results: Profit rises 54% to Rs 81.3 cr, revenue up 10%

The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu